Keywords: favorable, tox, profile, bionovo, bzl101, drugmaker, focused

Favorable tox profile for Bionovo's BZL101

Article | 19 December 2005

Print This

Bionovo, a US drugmaker focused on cancer, says that encouraging Phase I data on its oral drug candidate, BZL101, were ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in